Which anti diabetics are safe for a low eGFR?

Question

Hi doctor,

I am 56 years old, and my HbA1c has increased to 8.4%. My average fasting blood glucose is 168 mg/dL, and my postprandial levels are approximately 220 mg/dL. I am currently taking Metformin 1000 mg twice daily and Glipizide 5 mg. My estimated glomerular filtration rate (eGFR) is 68 mL/min/1.73 m², and my body mass index (BMI) is 32. My physician is considering initiating either a GLP-1 receptor agonist or an SGLT2 inhibitor.

Which of these options offers superior cardiovascular and renal protection? Additionally, are there risks of diabetic ketoacidosis (DKA) or urinary tract infections associated with these medications? Once treatment is initiated, how frequently should renal function and ketone levels be monitored?

Please help me.

Answer 1

Hello,

Welcome to icliniq.com.

I understand how frustrating it can be when blood glucose levels rise despite adherence to current medications. You are asking insightful questions regarding organ protection, which is precisely the focus at this stage of management. Let us break it down:

Cardiovascular and renal protection:

GLP-1 receptor agonists (such as Semaglutide or Ozempic): These agents provide significant cardiovascular protection by reducing the risk of heart attacks and strokes. They are also effective in promoting weight loss, which is particularly beneficial given your current BMI of 32.
SGLT2 inhibitors (such as Empagliflozin/ or Jardiance): These are considered the preferred option for renal protection, as they slow the decline in eGFR. They also offer substantial benefits in preventing heart failure.

Safety considerations:

SGLT2 Inhibitors: These may increase the risk of urinary tract and genital yeast infections, particularly in individuals who are not adequately hydrated. Although rare in type 2 diabetes, they can also cause euglycemic diabetic ketoacidosis (DKA). If you experience symptoms such as nausea, vomiting, or abdominal pain, especially during illness, it is advisable to check ketone levels.
GLP-1 receptor agonists: The most common side effect is nausea, especially at the start of therapy; however, this typically improves with time. These agents carry a low risk of hypoglycemia when not combined with insulin or sulfonylureas.

Monitoring requirements:

Prior to initiating therapy, assess eGFR and serum potassium and screen for any urinary tract infections. Once treatment is initiated, renal function should be monitored every three to six months. It is advisable to keep ketone testing strips at home and to test only if you are feeling unwell or exhibit symptoms suggestive of DKA. I hope this answer helps you.

Thank you.